Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
NBY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $4.44
Previous CloseN/A
Volume41.84K
Average Volume (3M)14.60M
Market Cap
$13.15M
Enterprise Value-$1.06M
Total Cash (Recent Filing)$5.34M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 06, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 30, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding6,005,749
10 Day Avg. Volume1,152,918
30 Day Avg. Volume14,603,156
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-0.22
Enterprise Value/Gross Profit-0.35
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$1.50Price Target Upside-31.51% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Asset SaleNovaBay accepted an increased offer of $11.5 million for its Avenova assets, which may benefit the company's financial position.
Business StrategyThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Bears Say
Financial PerformanceNet loss was $1.6 million or EPS of $(1.37) compared with our estimates of $(1.28) and consensus of $(1.23).
Investor UncertaintyThe company did not provide 2024 guidance, which creates uncertainty for investors.
Revenue PerformanceRevenue was $2.4 million compared with our estimates of $2.8 million and consensus of $3.2 million.
NovaBay Pharma News
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.46 and its highest was $4.44 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Novabay Pharmaceuticals’s market cap is $13.15M.
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.33.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Overvalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals pays a Notavailable dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Novabay Pharmaceuticals dividends here
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 6,005,749 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$0.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products for the eye care and wound care markets. The company leverages its proprietary technology platform, which includes its lead product, Avenova, a hypochlorous acid solution designed for eyelid and eyelash hygiene. NovaBay operates primarily in the healthcare sector, with a strong emphasis on addressing unmet medical needs in the prevention and treatment of infections.
Technical Analysis
Soligenix
―
Jaguar Animal Health
―
Evaxion Biotech
―
SciSparc Ltd.
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
17.03% Insiders
0.61% Mutual Funds
2.67% Other Institutional Investors
79.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---